Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness

@article{Post2007ThirtyYO,
  title={Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness},
  author={Robert M. Post and Terence A. Ketter and Thomas W Uhde and James C. Ballenger},
  journal={CNS Drugs},
  year={2007},
  volume={21},
  pages={47-71}
}
Carbamazepine began to be studied in a systematic fashion in the 1970s and became more widely used in the treatment of bipolar disorder in the 1980s. Interest in carbamazepine has been renewed by (i) the recent US FDA approval of a long-acting preparation for the treatment of acute mania; (ii) studies suggesting some efficacy in bipolar depression; and (iii) evidence of prophylactic efficacy in some difficult-to-treat subtypes of bipolar illness. A series of double-blind controlled studies of… Expand
[Lithium and anticonvulsants in bipolar depression].
TLDR
Lamotrigine is more effective on the depressive pole of bipolar disorder with better evidence for the prevention of depressive recurrences and the different safety/efficacy ratios of mood stabilizers underlie the complementarity and the importance of combination between them. Expand
The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study.
TLDR
Based on the results of the present and previous studies, it is suggested that CBZ might be considered an alternative in the management of certain conditions in major depressive disorder. Expand
Pharmacological treatment of acute bipolar depression
TLDR
This chapter addresses the challenges of treating bipolar depression by describing a general schema consisting of principles for iterative personalized care that can be applied to an evolving knowledge base. Expand
Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice
TLDR
A behaviourally effective oral and chronic regimen for carbamazepine with mood stabilising-like activity in a standard model for mania- like behaviour and two standard models for depression-like behaviour is demonstrated. Expand
Advances in the Pharmacotherapy of Bipolar Affective Disorder
TLDR
This chapter reviews the recent advances in the pharmacotherapy of bipolar affective disorder, the management of which is constantly evolving due to better understanding of its pathophysiology and introduction of new drug treatments. Expand
Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy
TLDR
The data suggest that epilepsy patients on LTG have better performance on phonemic fluency and the task of Stroop Color-Word Interference than do patients on CBZ, whereas patients onCBZ had more favorable behavioral effects on two subscales and two global scores of Symptom Check List-90 than did patients onLTG. Expand
Beyond the Guidelines for Bipolar Disorder: Practical Issues in Long-Term Treatment with Lithium
  • C. Calkin, M. Alda
  • Psychology, Medicine
  • Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2012
TLDR
Focus was on specific practical issues of lithium treatment, including the selection and initiation of long-term treatment, and management and discontinuation (if indicated) of lithium prophylaxis. Expand
16 Advances in the Pharmacotherapy of Bipolar Affective Disorder
Bipolar affective disorder is a chronic, relapsing and remitting mental illness with lifetime risk between 0.5 and 1.6% worldwide (Weissman et al. 1996). This prevalence increases to 5.5% for bipolarExpand
Use and safety of antiepileptic drugs in psychiatric inpatients—data from the AMSP study
TLDR
The psychiatric utilization patterns and risks of antiepileptic drugs (AEDs) were assessed by using data from the drug safety programme Arzneimittelsicherheit in der Psychiatrie over the time period 1993–2013, with main indications for AED use being acute mania, schizoaffective disorder, and schizophrenic and organic psychoses. Expand
Towards the clinical implementation of pharmacogenetics in bipolar disorder
TLDR
It is argued that based on the sufficiency of accumulated evidence, PGT implementation studies are now warranted and the design for a randomized clinical trial to test the use of PGT in the treatment of BD is proposed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 168 REFERENCES
Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.
TLDR
These prospective, randomized data suggest a high incidence of inadequate response to either mood stabilizer or their combination despite use of adjunctive agents as needed in large numbers of bipolar outpatients. Expand
Profile of clinical efficacy and side effects of carbamazepine in psychiatric illness
TLDR
Evidence of the usefulness of this anticonvulsant agent in manic and depressive illness cannot be taken as evidence that an ictal process underlies affective symptomatology, as it is clear that carbamazepine is useful in pain syndromes such as trigeminal neuralgia that do not involve an ICTal process. Expand
Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up.
TLDR
Clinical and mechanistic implications of these findings are discussed, including the phenomenon of contingent tolerance as a possible explanation for the emergence of loss of efficacy in a subgroup of patients. Expand
Differential Efficacy of Lithium and Carbamazepine in the Prophylaxis of Bipolar Disorder: Results of the MAP Study
TLDR
Lithium appears to be superior to carbamazepine in classical bipolar cases and might have additional impact on proneness to suicide and the distinctly larger group of patients with nonclassical features might profit more from carbazepine which seems to be well accepted by the patients. Expand
Use of Carbamazepine in Acute Psychosis: A Controlled Study
TLDR
Results confirm that CBZ is a valid alternative to lithium in the treatment of acute psychosis and no clinically relevant differences were found between the two groups. Expand
Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients.
TLDR
Lithium appears to be superior in prophylactic efficacy to carbamazepine in bipolar patients not previously treated with mood stabilizers, and should reinforce efforts to put and maintain such patients on treatment with lithium. Expand
A history of investigation on the mood stabilizing effect of carbamazepine in Japan
TLDR
Whether the difference in therapeutic dosages between Japan and Western countries is due to biological factors or to psychosocial and cultural factors is an important problem in psychopharmacology and should be investigated further. Expand
Carbamazepine compared with lithium in the treatment of mania.
TLDR
Patients receiving carbamazepine were somewhat more manageable than patients treated with lithium early in the study, whereas lithium-treated patients remained longer in the follow-up phase, however, numbers of long-term survivors were too small to be conclusive. Expand
Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.
TLDR
Lithium seems to be superior to carbamazepine in treating classical bipolar cases and patients with nonclassical features might profit more from prophylaxis with carbamazetine, which seems to have a broader spectrum of activity. Expand
Drug treatment of mania: a critical review
  • R. Licht
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica
  • 1998
TLDR
It is concluded that antipsychotics are powerful antimanics, which are particularly beneficial for some clinical presentations of severe mania, however, in general their use should not be prolonged into the maintenance phase. Expand
...
1
2
3
4
5
...